Omalizumab is best described as which type of agent and for which conditions is it typically indicated?

• A. An anti-IgE monoclonal antibody that reduces free IgE; indicated for moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria in selected cases.
• B. A short-acting beta-2 agonist used for immediate relief in asthma.
• C. A leukotriene receptor antagonist used for seasonal allergies.
• D. A corticosteroid inhaler used for long-term control.

Answer: (A)

Omalizumab is an anti-IgE monoclonal antibody that binds circulating free IgE, preventing it from attaching to FcεRI receptors on mast cells and basophils. By lowering free IgE and reducing receptor expression, it dampens the allergic cascade that leads to wheezing, inflammation, and urticaria. This targeted approach makes it a useful add-on therapy for patients with moderate-to-severe persistent allergic asthma whose symptoms aren’t well controlled despite inhaled corticosteroids, especially in those with a perennial allergen sensitivity. It’s also indicated in selected cases of chronic idiopathic (chronic spontaneous) urticaria, typically in adults and adolescents who have not responded adequately to antihistamines.

This drug is not a quick-relief bronchodilator like a short-acting beta-2 agonist, nor is it a leukotriene receptor antagonist or a corticosteroid inhaler, so its use and mechanism reflect a specific allergy-driven strategy rather than immediate symptom relief or non-IgE pathways.